Brendan O'Boyle
Long only, value, growth at reasonable price, medium-term horizon

Tetraphase Pharmaceuticals: A Compelling High-Risk / High-Reward Biotech Investment

After many years of antibiotic over prescription, multi-drug-resistant ((NYSE:MDR)) bacterial infections are a serious threat to our nation's health. It is estimated that over 3.5 million cases of MDR infection are encountered each year in the United States. The figure below summarizes the increasing incidence of antibiotic resistant bacteria. More recently, bacteria have evolved to resist even the most potent antibiotics, such as vancomycin, which comprise the last line of defense against MDR bacterial infection.

Figure 1: Thirty Years of Increasing Antibiotic Resistance

Source: Centers for Disease Control and Prevention

MRSA = methicillin-resistant staphylococcus aureus; FQRP = fluoroquinolone-resistant pseudomonas aeruginosa and VRE = vancomycin-resistant enterococci.

Despite this huge unmet medical need, limited resources have been deployed toward...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details